SNPX News and Press, Synaptogenix Inc. From 02/25/21

Synaptogenix to Present at Upcoming Scientific Industry Conferences PR Newswire NEW YORK , Feb. 25, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases...

Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference PR Newswire NEW YORK , Feb. 12, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for...

Synaptogenix Files Application to List on the Nasdaq Stock Market PR Newswire NEW YORK , Feb. 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) (the "Company"), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative...

Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials PR Newswire NEW YORK , Feb. 4, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin. The Company has an e...

New Study Demonstrates Bryostatin Normalizes Autistic Spectrum Behaviors in Mice - Peer Reviewed Article Published through Nature.com PR Newswire NEW YORK , Jan. 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience...

Synaptogenix (SNPX) formerly Neurotrope Bioscience, to raise ~$14M in a private placement of common stock at $1.50/share, one-year warrants to purchase an equal number of common stock at $2.1275 and five-year warrants to purchase an equal number of common stock at $1.725 per share. Proceeds w...

Synaptogenix Announces $14.0 Million Private Placement - Fully Funds Phase 2 Alzheimer's Disease Trial Being Conducted in Partnership with The National Institutes of Health - Provides Pathway for Strategic Partnerships on Other Indications PR Newswire NEW YORK ...

Synaptogenix Schedules Business Update Conference Call NEW YORK , Dec. 15, 2020 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., announced the successful spin-off of substantially all of the legacy assets and liabilities of ...